neurology

Biotech By Kate Sheridan

4 questions for neurology startups as venture investors pour millions into the field

Health By Elizabeth Cooney

Long after the fire of a Covid-19 infection, mental and neurological effects can still smolder

Health By Andrew Joseph

When Covid-19 hits the brain, it can cause strokes, psychosis and a dementia-like syndrome, new survey shows  

In the Lab By Natalya Ortolano

A preliminary new method could restore the brain cells Parkinson’s disease patients lost

Pharmalot By Ed Silverman

Pharmalittle: WHO sets goals for distributing Covid-19 treatments; new warnings urged on diabetes drugs

Biotech By Elizabeth Cooney

Startup Spotlight: Aiming to speed precision cancer therapies to children

The Readout LOUD By Damian Garde and Rebecca Robbins

Listen: Covid-19 in the White House, an audacious approach to Parkinson’s, and the public health lessons from porn

Health By Sharon Begley

Ethics questions swirl around historic Parkinson’s experiment

In the Lab By Elizabeth Cooney

A ‘sniff test’ signals consciousness after a brain injury, study shows

Biotech By Kate Sheridan

Two companies bet on ‘chemogenetics’ to sidestep challenges with neurological drug development 

First Opinion By Meredith O'Brien

A chronic illness conundrum: Should I tell my employer about my MS?

First Opinion By Keita Mori

The U.S. needs a nationwide registry for traumatic brain injury

In the Lab By Sharon Begley

They have ‘Alzheimer’s brains’ but no symptoms. A new wave of drug developers wants to know why

Pharmalot By Ed Silverman

ICER, the controversial cost-effectiveness watchdog, reverses course on two migraine drugs

Pharmalot By Ed Silverman

Rising out-of-pocket costs for dementia and neuropathy drugs lower patient adherence

First Opinion By Donna Jackson Nakazawa

Microglia: a new target in the brain for depression, Alzheimer’s, and more?

Biotech By Matthew Herper

A venture firm warms to funding neuroscience

Pharmalot By Ed Silverman

High cost of multiple sclerosis medicines is forcing many patients to take ‘drastic actions’

Biotech By Jonathan Saltzman — Boston Globe

An uncommon form of dementia hits at a younger age. Drug makers are searching for a treatment

Biotech By Jonathan Saltzman — Boston Globe

Startup targeting DNA repeats in Huntington’s and other diseases debuts with $59 million

Health By Felice J. Freyer — Boston Globe

After Ice Bucket campaign, researchers have optimism about insights into ALS puzzle

In the Lab By Sharon Begley

Research using brains-in-a-dish forces a radical rethinking of Huntington’s disease

Health By Andrew Joseph

A clinical trial for Huntington’s opens the door to hope for some patients. Only so many can get in

In the Lab By Elizabeth Cooney

Warning: Swimming and deep brain stimulation do not mix

Pharmalot By Ed Silverman

Biogen is criticized by the National Multiple Sclerosis Society over pricing for its new pill